Karen Lewis
CIK 1814304 · Chief People Officer · last filed 2025-01-30
Karen Lewis is a Chief People Officer who has filed 21 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing shows the insider sold $10.7K of APLS on Jan 30, 2025. Across all open-market trades the lifetime net is −$2.0M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
21
-$2.02M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief People Officer | 70,251 | $41.03 | $2.88M | -$2.02M | 21 | 2025-01-30 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −364 | -$10.7K | EDGAR |
| 2025-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,751 | -$53.3K | EDGAR |
| 2025-01-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +27,267 | -$37.2K | EDGAR |
| 2025-01-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,599 | -$45.9K | EDGAR |
| 2024-01-31 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,250 | -$81.4K | EDGAR |
| 2024-01-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −4,286 | -$273.0K | EDGAR |
| 2024-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,738 | -$113.0K | EDGAR |
| 2024-01-18 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −3,276 | -$214.8K | EDGAR |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +15,331 | -$109.0K | EDGAR |
| 2023-06-02 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | — | -$259.4K | EDGAR |